Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

IRAK-1 inhibitor

DRUG CLASS:

IRAK-1 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	SB939 + pacritinib Sensitive: D – Preclinical SB939 + pacritinib Sensitive : D	SB939 + pacritinib Sensitive: D – Preclinical SB939 + pacritinib Sensitive : D
JAK2 V617F	Acute Myelogenous Leukemia	JAK2 V617F	Acute Myelogenous Leukemia	SB939 + pacritinib Sensitive: D – Preclinical SB939 + pacritinib Sensitive : D	SB939 + pacritinib Sensitive: D – Preclinical SB939 + pacritinib Sensitive : D
MYD88 mutation	Diffuse Large B Cell Lymphoma	MYD88 mutation	Diffuse Large B Cell Lymphoma	pacritinib Sensitive: D – Preclinical pacritinib Sensitive : D	pacritinib Sensitive: D – Preclinical pacritinib Sensitive : D